Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/3/2025

Management of Pulmonary Sarcoidosis with Secondary Erythrocytosis

Assessment and Diagnosis

  • Secondary erythrocytosis in pulmonary sarcoidosis patients is typically a compensatory response to chronic hypoxemia caused by the underlying lung disease, as noted by the European Heart Journal 1
  • Elevated reticulocytes and LDH suggest active erythropoiesis in response to tissue hypoxia, according to the European Heart Journal 1
  • Patients should be evaluated for symptoms of hyperviscosity, including headaches, visual disturbances, fatigue, and reduced exercise tolerance, as recommended by the European Heart Journal 1

Management Algorithm

  • For symptomatic pulmonary sarcoidosis patients at high risk of mortality or permanent disability, the European Respiratory Journal recommends initiating glucocorticoid treatment (prednisone) to improve/preserve lung function and quality of life 2, 3, 4
  • The European Respiratory Journal suggests adding methotrexate as second-line therapy for patients with continued disease despite glucocorticoids or experiencing unacceptable side effects 2, 4, 5
  • Infliximab may be considered as third-line therapy for refractory cases, as noted by the European Respiratory Journal 2, 5

Management of Secondary Erythrocytosis

  • Therapeutic phlebotomy should only be performed when hematocrit exceeds 65% and the patient has moderate to severe hyperviscosity symptoms, using isovolumic fluid replacement, as recommended by the European Heart Journal 1
  • Iron management is crucial, with monitoring for iron deficiency and provision of iron supplementation if necessary, while avoiding iron deficiency due to its association with increased risk of cerebrovascular events, according to the European Heart Journal 1
  • Blood transfusion should be considered only if iron-replete anemia is present with inadequate hemoglobin for oxygen saturation, as noted by the European Heart Journal 1

Monitoring and Follow-up

  • Regular monitoring of oxygen saturation at rest and with ambulation is recommended, as suggested by the Journal for ImmunoTherapy of Cancer 6
  • Pulmonary function tests should be performed to assess disease progression, according to the European Respiratory Journal 2, 3
  • Complete blood count and iron studies should be monitored to prevent deficiency and manage erythrocytosis, as recommended by the European Heart Journal 1
  • Follow-up visits every 6-12 months in a specialized center are advised, as noted by the European Heart Journal 1

Important Considerations and Pitfalls

  • Microcytosis due to iron deficiency from inappropriate phlebotomies is the strongest independent predictor for cerebrovascular events in patients with cyanotic conditions, as reported by the European Heart Journal 1
  • Dehydration should be avoided as it can worsen hyperviscosity symptoms, according to the European Heart Journal 1
  • Routine anticoagulation or aspirin therapy should not be used as there is no proven benefit in preventing thromboembolic complications in cyanotic patients, and there is an increased risk of bleeding, as noted by the European Heart Journal 1